Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Mark, Midei"'
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-9 (2020)
Abstract Background INAD is an autosomal recessive neurogenetic disorder caused by biallelic pathogenic variants in PLA2G6. The downstream enzyme, iPLA2, plays a critical role in cell membrane homeostasis by helping to regulate levels of phospholipid
Externí odkaz:
https://doaj.org/article/45a665d458d64ca49587a093f9d6e00b
Autor:
Darius Adams, Mark Midei, Jahannaz Dastgir, Christina Flora, Robert J Molinari, Frederic Heerinckx, Sarah Endemann, Paldeep Atwal, Peter Milner, Mikhail S. Shchepinov
Publikováno v:
JIMD Reports, Vol 54, Iss 1, Pp 54-60 (2020)
Abstract Background Infantile neuroaxonal dystrophy (INAD) is a rare, autosomal recessive disease due to defects in PLA2G6 and is associated with lipid peroxidation. RT001 is a di‐deuterated form of linoleic acid that protects lipids from oxidative
Externí odkaz:
https://doaj.org/article/39110a888b0543f1bda4a330bf80b067
Autor:
Fadie D. Altuame, Gretchen Foskett, Paldeep S. Atwal, Sarah Endemann, Mark Midei, Peter Milner, Mustafa A. Salih, Muddathir Hamad, Mohammad Al-Muhaizea, Mais Hashem, Fowzan S. Alkuraya
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-12 (2020)
Abstract Background Infantile neuroaxonal dystrophy (INAD) is a rapidly progressive neurodegenerative disorder of early onset causing premature death. It results from biallelic pathogenic variants in PLA2G6, which encodes a calcium-independent phosph
Externí odkaz:
https://doaj.org/article/38b21d6aee494db4baefdb793f62873e
Autor:
David R. Lynch, Katherine D. Mathews, Susan Perlman, Theresa Zesiewicz, Sub Subramony, Omid Omidvar, Adam P. Vogel, Ana Krtolica, Nadia Litterman, Lex van der Ploeg, Frederic Heerinckx, Peter Milner, Mark Midei
Publikováno v:
Journal of neurology.
Friedreich ataxia is (FRDA) an autosomal recessive neurodegenerative disorder associated with intrinsic oxidative damage, suggesting that decreasing lipid peroxidation (LPO) might ameliorate disease progression. The present study tested the ability o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b4b7205ef5ec666572b45ac2481e0d
https://pubmed.ncbi.nlm.nih.gov/36462055
https://pubmed.ncbi.nlm.nih.gov/36462055
Autor:
J. Tift Mann, Mark Midei, Charles O'Shaughnessy, Timothy D. Henry, Louis Cannon, Jeffrey J. Popma, David O. Williams, Paul Overlie, Jessie Coe, Alan C. Yeung, Thomas Stuckey, Robert Whitbourn, James B. Hermiller, Peter J. Fitzgerald, William A. Gray, Hubertus Heuer, Lewis B. Schwartz, Donald E. Cutlip
Publikováno v:
International Journal of Cardiology. 157:96-101
Background/Objectives The purpose of this prospective, randomized, single-blind controlled clinical trial was to compare the effectiveness of a zotarolimus-eluting stent (ZoMaxx™) with a paclitaxel-eluting coronary stent (Taxus™ Express 2 ™) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c81cdcc1d37cb1a34d7a86bd87b0e137
https://doi.org/10.1016/j.ijcard.2011.05.061
https://doi.org/10.1016/j.ijcard.2011.05.061
Autor:
Charles O'Shaughnessy, Alexandra J. Lansky, Sheldon Goldberg, Ecaterina Cristea, Gregg W. Stone, Robert M. Siegel, Roxana Mehran, George Dangas, Mark Midei
Publikováno v:
JACC: Cardiovascular Interventions. 4:300-309
Objectives: We sought to evaluate the utility of the JOSTENT polytetrafluoroethylene (PTFE) stent-graft (Jomed GmbH, Rangendingen, Germany) in patients with diseased saphenous vein grafts (SVGs) un...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fda54250845320aa046f035f2a63af70
https://doi.org/10.1016/j.jcin.2010.11.013
https://doi.org/10.1016/j.jcin.2010.11.013
Autor:
Julian Benetato Guiran, Gregg W. Stone, Mark Sanz, Ecaterina Cristea, Roseann White, William G. Newman, Halil Mutlu, Xiaolu Su, Poornima Sood, Alexandra J. Lansky, Vivian Ng, Julie Doostzadeh, Sherry Cao, Krishnankutty Sudhir, Mark Midei
Publikováno v:
Catheterization and Cardiovascular Interventions. 74:719-727
Objectives: We evaluated the role of gender on clinical and angiographic results of the everolimus-eluting stent in the SPIRIT III trial. Background: The SPIRIT III trial demonstrated superior efficacy of the XIENCE V everolimus-eluting stent compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896b36820317b43d58de14377d87ad8b
https://doi.org/10.1002/ccd.22067
https://doi.org/10.1002/ccd.22067
Publikováno v:
International Journal of Clinical Practice. 60:863-866
Summary Therapy with aspirin and/or adenosine diphosphate (ADP) receptor blockers is associated with better outcomes via inhibition of platelet activity, and subsequent reduction of ischemic vascular events. Non-compliance (NC) is a well-recognised h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::021640ca9ea4cba7aa797d68559575b6
https://doi.org/10.1111/j.1742-1241.2006.00999.x
https://doi.org/10.1111/j.1742-1241.2006.00999.x
Autor:
Mark Midei, Peter J. Fitzgerald, Sejal S. Badre, Richard Kuntz, Laura Mauri, Charles O'Shaughnessy, Mark Turco, David E. Kandzari, Robert J. Applegate, Jeffrey J. Popma, Michael W. Ball, LeRoy A. LeNarz, Kweli P. Thompson, Endeavor Iii Investigators, Martin B. Leon, Paul A. Gurbel
Publikováno v:
Journal of the American College of Cardiology. 48:2440-2447
Objectives This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES). Background Whether a cobalt-based al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4afab917c78445ecab30444fa48fb1f3
https://doi.org/10.1016/j.jacc.2006.08.035
https://doi.org/10.1016/j.jacc.2006.08.035
Autor:
Vicki J. Coombs, Mark Midei, David R. Lowry, Sidney O. Gottlieb, Michael N. Drossner, Michele B. Loughrey, John C. Wang, Kerry C. Prewitt
Publikováno v:
Cardiology. 107:172-177
Background: Randomized clinical trials comparing glycoprotein IIb-IIIa inhibitors have largely excluded patients with ST segment elevation myocardial infarction (STEMI). Methods: We conducted an open-label, sequential comparison of inhospital and 6-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2bbee02888979b2006affa12d22800a
https://doi.org/10.1159/000095343
https://doi.org/10.1159/000095343